Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on Oct...
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)
- Conditions
- Interventions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 133
- Registration Number
- NCT00837577
The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 10
- Registration Number
- NCT00832624
Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM
- Conditions
- Interventions
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2013-12-13
- Target Recruit Count
- 16
- Registration Number
- NCT00820573
- Locations
- 🇺🇸
Texas Diabetes Institute, San Antonio, Texas, United States
Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14671
- Registration Number
- NCT00790205
Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 222
- Registration Number
- NCT00789191
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Kocaeli, Turkey
Response To Oral Agents in Diabetes (ROAD)- Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2008-10-28
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 29
- Registration Number
- NCT00780715
- Locations
- 🇬🇧
Ninewells Hospital & Medical School, Dundee, United Kingdom
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
- Conditions
- Interventions
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 47
- Registration Number
- NCT00775684
- Locations
- 🇺🇸
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Clinical and Translational Research Center, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Rodebaugh Diabetes Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 75
- Registration Number
- NCT00770081
- Locations
- 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸Emory Clinic, Atlanta, Georgia, United States
🇺🇸Renal Endocrine Associates, P. C., Pittsburgh, Pennsylvania, United States
Incretin Effect and Use After Clinical Islet Transplantation
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2015-06-18
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 8
- Registration Number
- NCT00768651
- Locations
- 🇨🇦
University of Alberta - Clinical Islet Transplant Program, Edmonton, Alberta, Canada
Sitagliptin Versus Sulphonylurea in Type 2 Diabetes During Ramadan
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- University of Manchester
- Target Recruit Count
- 22
- Registration Number
- NCT00766441
- Locations
- 🇬🇧
Wellcome Trust Clinical Research Facility, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.